Lumen Bioscience Secures DOD Funding for Infection Treatment 

Seattle-based biotech company Lumen Bioscience received $16.2M from the U.S. Department of Defense to support the development of its C. difficile treatment. The award will be used to fund Lumen’s drug trials. The company plans to recruit nearly 400 hospitalized patients across the country to participate in the study.

“What we want to do is find people who have been newly diagnosed with this infection,” said Brian Finrow, CEO of Lumen Bioscience. “These people are very vulnerable, particularly the ones who are in the hospital.”

In addition to its C. difficile treatment, which utilizes therapeutic proteins, Lumen is also working towards treatments for COVID-19, Crohn’s disease, ulcerative colitis and metabolic disease.